Trulieve Cannabis Past Earnings Performance
Past criteria checks 0/6
Trulieve Cannabis's earnings have been declining at an average annual rate of -73.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 37.4% per year.
Key information
-73.1%
Earnings growth rate
-68.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 37.4% |
| Return on equity | -30.9% |
| Net Margin | -38.1% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Trulieve Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,129 | -431 | 386 | 0 |
| 30 Sep 23 | 1,162 | -477 | 414 | 0 |
| 30 Jun 23 | 1,182 | -527 | 427 | 0 |
| 31 Mar 23 | 1,214 | -205 | 432 | 0 |
| 31 Dec 22 | 1,218 | -179 | 422 | 0 |
| 30 Sep 22 | 1,225 | -185 | 408 | 0 |
| 30 Jun 22 | 1,153 | -95 | 376 | 0 |
| 31 Mar 22 | 1,055 | -37 | 339 | 0 |
| 31 Dec 21 | 932 | 31 | 296 | 0 |
| 30 Sep 21 | 801 | 93 | 229 | 0 |
| 30 Jun 21 | 714 | 91 | 202 | 0 |
| 31 Mar 21 | 619 | 69 | 179 | 0 |
| 31 Dec 20 | 522 | 63 | 151 | 0 |
| 30 Sep 20 | 433 | -19 | 132 | 0 |
| 30 Jun 20 | 367 | 23 | 111 | 0 |
| 31 Mar 20 | 304 | 62 | 91 | 0 |
| 31 Dec 19 | 253 | 53 | 73 | 0 |
| 30 Sep 19 | 209 | 128 | 70 | 0 |
| 30 Jun 19 | 167 | 85 | 60 | 0 |
| 31 Mar 19 | 132 | 36 | 51 | 0 |
| 31 Dec 18 | 103 | 11 | 44 | 0 |
| 30 Sep 18 | 80 | 33 | 23 | 0 |
| 30 Jun 18 | 55 | 16 | 17 | 0 |
| 31 Mar 18 | 33 | 9 | 12 | 0 |
| 31 Dec 17 | 20 | 4 | 8 | 0 |
| 31 Dec 16 | 0 | -4 | 1 | 0 |
Quality Earnings: TCNN.F is currently unprofitable.
Growing Profit Margin: TCNN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCNN.F is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.
Accelerating Growth: Unable to compare TCNN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCNN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: TCNN.F has a negative Return on Equity (-30.95%), as it is currently unprofitable.